Innovative Molecules (IM), a clinical-stage biopharmaceutical company focused on herpesvirus-mediated diseases, has advanced its virology pipeline by adding a novel Epstein-Barr Virus (EBV) antiviral program.
The program consists of several directly acting, highly potent targeted polymerase inhibitors and is planned to advance to Phase 1 in 2027.
EBV is associated with several serious diseases, including lymphoproliferative disorders, transplant-related complications, and autoimmune conditions, while approved targeted antiviral treatment options remain limited.
The new program is an important expansion of IM’s development activities in herpesvirus-associated diseases and reinforces the company’s focus on differentiated antiviral therapeutics that address unmet medical needs.
CEO, Innovative Molecules, Florian Vogel, said, “EBV is an increasingly important therapeutic area with substantial medical need, while growing momentum in both scientific research and therapeutic development. The addition of this program marks an important step in the continued expansion of our antiviral pipeline and reinforces our commitment to advancing innovative therapeutic approaches for serious viral diseases.”
The EBV program complements IM’s broader strategy to build a focused portfolio of differentiated virology assets with the potential to address high-value indications where current treatment options remain limited.
